Nose-to-Brain: Sterling accelerating innovation in inhalation therapies.

Nose-to-Brain: Sterling accelerating innovation in inhalation therapies. The nose can serve as a direct gateway to the brain. This is the frontier explored by Nose-to-Brain strategies — among the most promising developments in drug delivery, particularly for central nervous system (CNS) treatments. Sterling plays an active role in the INTO - Inhalation Together alliance, stablished in 2022 alongside DFE Pharma and Harro Höfliger. Three companies, three areas of expertise, one shared vision: to simplify and accelerate the development of dry powder inhalation (DPI) formulations.  

Nose-to-Brain: Sterling accelerating innovation in inhalation therapies. The nose can serve as a direct gateway to the brain. This is the frontier explored by Nose-to-Brain strategies — among the most promising developments in drug delivery, particularly for central nervous system (CNS) treatments. Sterling plays an active role in the INTO - Inhalation Together alliance, stablished in 2022 alongside DFE Pharma and Harro Höfliger. Three companies, three areas of expertise, one shared vision: to simplify and accelerate the development of dry powder inhalation (DPI) formulations.  

What does Sterling contribute? With over 30 years of experience in respiratory APIs, Sterling provides: - Engineered APIs for inhalation and nasal delivery, including LABAs, LAMAs, and neurosteroids - Advanced particle engineering technologies such as sono-crystallization, spray drying, and controlled precipitation - Pre-formulation and physicochemical characterization, essential for defining morphology, particle size, flowability, and stability - End-to-end support, from early-stage development to industrial production and lifecycle management Within the INTO alliance, Sterling focuses on API development and dry powder formulations designed for nasal administration targeting the nose-to-brain route, helping to overcome the blood–brain barrier. One gateway, multiple competencies: Thanks to the synergy between partners, INTO offers a holistic approach — from excipient screening and device optimization to regulatory studies — with Sterling as the API and particle engineering reference. For us, Nose-to-Brain is not only a scientific opportunity, but a strategic pathway to reformulate existing drugs, develop complex generics, and accelerate time-to-market in high-potential therapeutic areas. Proud to advance inhalation innovation as part of the INTO Alliance.

What does Sterling contribute? With over 30 years of experience in respiratory APIs, Sterling provides: - Engineered APIs for inhalation and nasal delivery, including LABAs, LAMAs, and neurosteroids - Advanced particle engineering technologies such as sono-crystallization, spray drying, and controlled precipitation - Pre-formulation and physicochemical characterization, essential for defining morphology, particle size, flowability, and stability - End-to-end support, from early-stage development to industrial production and lifecycle management Within the INTO alliance, Sterling focuses on API development and dry powder formulations designed for nasal administration targeting the nose-to-brain route, helping to overcome the blood–brain barrier. One gateway, multiple competencies: Thanks to the synergy between partners, INTO offers a holistic approach — from excipient screening and device optimization to regulatory studies — with Sterling as the API and particle engineering reference. For us, Nose-to-Brain is not only a scientific opportunity, but a strategic pathway to reformulate existing drugs, develop complex generics, and accelerate time-to-market in high-potential therapeutic areas. Proud to advance inhalation innovation as part of the INTO Alliance.